Alamar Biosciences' Proteomics Tech Reveals Divergent Alzheimer’s Treatment Responses — Alamar Biosciences, Inc.

Event summary

Alamar Biosciences' NULISAseq™ CNS 120 panel measured 130 plasma proteins in 2,385 samples from 1,967 Alzheimer’s patients treated with lecanemab.
Study found 34 of 130 biomarkers significantly changed with treatment, not all moving in the same direction.
Brain-derived tau proteins outperformed peripheral tau in distinguishing treated patients from controls.
Research led by Washington University School of Medicine, published in The Lancet Neurology on September 24, 2026.

The big picture

The study underscores the growing importance of precision proteomics in neurodegenerative disease research, particularly as anti-amyloid therapies become standard care. Alamar’s technology enables a more nuanced understanding of treatment responses, potentially reshaping how Alzheimer’s is managed. The findings could accelerate the adoption of proteomics platforms in clinical settings, positioning Alamar as a key player in the evolving landscape of biomarker-driven diagnostics.

What we're watching

Biomarker Differentiation: How Alamar’s ability to distinguish brain-derived tau from peripheral tau will impact future Alzheimer’s research.
Treatment Response Variability: Whether the divergent biomarker responses will lead to personalized treatment approaches for Alzheimer’s patients.
Proteomics Market Positioning: The pace at which Alamar can leverage this study to solidify its leadership in ultra-high sensitivity proteomics.